GHRP-6
GHRP-6, a synthetic growth hormone-releasing peptide, stimulates growth hormone release and has shown potential in various areas, including cardioprotection, wound healing, and potentially improving energy metabolism and muscle function.
Here's a more detailed breakdown of the potential benefits and research findings:
1. Cardioprotection:
Doxorubicin-induced toxicity:
GHRP-6 has demonstrated protective effects against doxorubicin (Dox), a chemotherapy drug, which can cause heart damage.
Mechanism:
GHRP-6 can help preserve myocardial fibers, prevent ventricular dilation, and maintain left ventricular systolic function.
Extracardiac effects:
It can also attenuate toxicity in other organs, preserving epithelial integrity and reducing fibrosis.
Antioxidant and pro-survival effects:
GHRP-6 sustains cellular antioxidant defense, upregulates the prosurvival gene Bcl-2, and preserves cardiomyocyte mitochondrial integrity.
2. Wound Healing:
Enhanced healing:
GHRP-6 can enhance the healing process and improve the aesthetic outcome of wounds.
Reduced inflammation and fibrosis:
GHRP-6 administration significantly enhanced wound closure and reduced inflammation markers and the expression of profibrogenic cytokines.
3. Energy Metabolism and Muscle Function:
Increased energy metabolites:
GHRP-6-biotin conjugate increases energy metabolites like ATP and lactate, which are important for muscle function.
Increased skeletal α-actin expression:
This conjugate also increases skeletal α-actin protein expression, which is closely related to muscle contraction.
4. Other Potential Benefits:
Neuroprotection:
GHRP-6 can increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in neuroprotection.
Immunomodulatory effects:
GHRP-6 has immunomodulatory effects in tilapia, potentially enhancing antimicrobial peptide genes and microbicidal activities.
Cytoprotective effects:
GHRP-6 has shown a systemic cytoprotective effect, suggesting its potential to control inflammatory responses and protect against organ damage.
Gastric emptying:
GHRP-6 can accelerate gastric emptying in diabetic mice.
GH Secretagogue:
GHRP-6 is a synthetic growth hormone-releasing peptide that stimulates the release of growth hormone from the pituitary gland.
Description – GHRP-6
Growth Hormone Releasing Peptide 6 (GHRP-6) is a synthetic, 6-amino acid sequence, which is analogous to the naturally occurring protein met-enkephalin1. GHRP-6 is a member of a classification of agents called growth hormone (GH) secretagogues that were collectively developed in an effort to artificially stimulate the release of GH2. GHRP-6 is known to bind with the GH secretagogue receptor (ghrelin receptor) directly3, stimulating potent GH secretion and appetite in animal test subjects2.The promotion of improved strength, increased muscle mass to body fat ratio, and the encouragement of good joint and connective tissue health has been observed in animal trials4. Studies in animal test subjects show that GHRP-6 stimulates Ghrelin, “the hunger hormone” through its ghrelin receptor, which in turn signals an increased production of growth hormone (GH) by acting at the level of the pituitary or hypothalamus through a specific receptor different from that of the endogenous Growth Hormone-Releasing Hormone GHRH.The four parts of the animal test subjects that demonstrate the role of GHRP-6 include the pituitary gland, central nervous system, liver, and stomach.
Product Comparison
Similar to other agents of GH release, GHRP-6 acts on the anterior pituitary gland5. In spite of having a similar site of action, GHRP-6 does not stimulate GH production using the same biochemical pathway as the popular GH secretagogue ‘sermorelin’ its analogues, like CJC-12956. In light of this observation, it has been possible for researchers to administrate CJC-1295 and GHRP-6 concurrently in order to achieve an additive positive effect on GH release. A similar synergistic relationship has been documented with insulin, where much improved GH release was observed in animal trials following a concurrent dosing scheme7.
The GHRP Family
The GHRP family of proteins is distinct from growth hormone releasing hormones (GHRH or GHRF) in that they share no sequence relation and derive their function through action at a completely different receptor, the ghrelin receptor8. The GHRP family is unique in that they lack opiate activity, though they are analogues of species that bear this quality9.
Research products only, they are not for human consumption.
Synonyms:
Growth Hormone Releasing Peptide-6; Growth hormone releasing hexapeptide; Somacrin; Somatocrinin-6; RP6;
Peer-Reviewed Sources:
McDowell RS, Elias KA, Stanley MS, Burdick DJ, Burnier JP, Chan KS, Fairbrother WJ, Hammonds RG, Ingle GS, Jacobsen NE (1995). Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation. Proc Natl Acad Sci USA, 92:11165-11169. ↩︎
Fairhall, K. M., Mynett, A., & Robinson, I. C. A. F. (1995). Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action. Journal of Endocrinology, 144(3), 555-560. ↩︎
Muccioli, G., Ghe, C., Ghigo, M. C., Papotti, M., Arvat, E., Boghen, M. F., Nilsson, H., Deghenghi, R., Ong, H., & Ghigo, E. (1998). Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland. Journal of Endocrinology, 157(1), 99-106. ↩︎
Cella, S. G., Cerri, C. G., Daniel, S., Sibilia, V., Rigamonti, A., Cattaneo, L., Deghenghi, R., & Müller, E. E. (1996). Sixteen weeks of hexarelin therapy in aged dogs: effects on the somatotropic axis, muscle morphology, and bone metabolism. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 51(6), B439-B447. ↩︎
Mau, S. E., Witt, M. R., Bjerrum, O. J., Særmark, T., & Vilhardt, H. (1995). Growth hormone releasing hexapeptide (GHRP-6) activates the inositol (1, 4, 5)-trisphosphate/diacylglycerol pathway in rat anterior pituitary cells. Journal of Receptors and Signal Transduction,15(1-4), 311-323. ↩︎
Cordido, F., Penalva, A., Dieguez, C., & Casanueva, F. F. (1993). Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. The Journal of Clinical Endocrinology & Metabolism, 76(4), 819-823. ↩︎
Penalva, A., Carballo, A., Pombo, M., Casanueva, F. F., & Dieguez, C. (1993). Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man. The Journal of Clinical Endocrinology & Metabolism, 76(1), 168-171. ↩︎
Granado, M., Priego, T., Martín, A. I., Villanua, M. A., & López-Calderón, A. (2005). Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. American Journal of Physiology-Endocrinology and Metabolism, 288(3), E486-E492. ↩︎
Casanueva, F. F., & Dieguez, C. (1999). Growth hormone secretagogues: physiological role and clinical utility. Trends in Endocrinology & Metabolism,10(1), 30-38. ↩︎
ALL LITERATURE, INFORMATION, AND DATA, PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.